Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 21;10(10):2657.
doi: 10.3390/biomedicines10102657.

Surgical Management of Synucleinopathies

Sai Sriram  1 , Kevin Root  1 , Kevin Chacko  1 , Aashay Patel  1 , Brandon Lucke-Wold  1
Affiliations

Surgical Management of Synucleinopathies

Sai Sriram et al. Biomedicines. .

Abstract

Synucleinopathies represent a diverse set of pathologies with significant morbidity and mortality. In this review, we highlight the surgical management of three synucleinopathies: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). After examining underlying molecular mechanisms and the medical management of these diseases, we explore the role of deep brain stimulation (DBS) in the treatment of synuclein pathophysiology. Further, we examine the utility of focused ultrasound (FUS) in the treatment of synucleinopathies such as PD, including its role in blood-brain barrier (BBB) opening for the delivery of novel drug therapeutics and gene therapy vectors. We also discuss other recent advances in the surgical management of MSA and DLB. Together, we give a diverse overview of current techniques in the neurosurgical management of these pathologies.

Keywords: Parkinson’s disease; deep brain stimulation; dementia with Lewy bodies; focused ultrasound; gene therapy; multiple system atrophy; surgical techniques; synucleinopathies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary of mechanisms by which DBS possibly confers a neuroprotective effect. Figure created with BioRender.com, accessed on 19 September 2022.
Figure 2
Figure 2
Summary of applications of focused ultrasound to synucleinopathies. Figure created with BioRender.com, accessed on 19 September 2022.
See this image and copyright information in PMC

References

    1. Kianirad Y., Simuni T. Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis. Expert Rev. Clin. Pharmacol. 2017;10:1161–1168. doi: 10.1080/17512433.2017.1369405. - DOI - PubMed
    1. Abrantes A.M., Friedman J.H., Brown R.A., Strong D.R., Desaulniers J., Ing E., Saritelli J., Riebe D. Physical Activity and Neuropsychiatric Symptoms of Parkinson Disease. J. Geriatr. Psychiatry Neurol. 2012;25:138–145. doi: 10.1177/0891988712455237. - DOI - PubMed
    1. Wickremaratchi M.M., Ben-Shlomo Y., Morris H.R. The effect of onset age on the clinical features of Parkinson’s disease. Eur. J. Neurol. 2009;16:450–456. doi: 10.1111/j.1468-1331.2008.02514.x. - DOI - PubMed
    1. Yang W., Hamilton J.L., Kopil C., Beck J.C., Tanner C.M., Albin R.L., Ray Dorsey E., Dahodwala N., Cintina I., Hogan P., et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Park. Dis. 2020;6:1–9. doi: 10.1038/s41531-020-0117-1. - DOI - PMC - PubMed
    1. De Souza R.M., Moro E., Lang A.E., Schapira A.H.V. Timing of Deep Brain Stimulation in Parkinson Disease: A Need for Reappraisal? Ann. Neurol. 2013;73:565–575. doi: 10.1002/ana.23890. - DOI - PMC - PubMed

LinkOut - more resources